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Antibiotic resistance poses rapidly increasing global problems in combatting multidrug-
resistant (MDR) infectious diseases like MDR tuberculosis, prompting for novel approaches
including host-directed therapies (HDT). Intracellular pathogens like Salmonellae and Myco-
bacterium tuberculosis (Mtb) exploit host pathways to survive. Only very few HDT compounds
targeting host pathways are currently known. In a library of pharmacologically active com-
pounds (LOPAC)-based drug-repurposing screen, we identify multiple compounds, which
target receptor tyrosine kinases (RTKs) and inhibit intracellular Mtb and Salmonellae more
potently than currently known HDT compounds. By developing a data-driven in silico model
based on confirmed targets from public databases, we successfully predict additional effi-
cacious HDT compounds. These compounds target host RTK signaling and inhibit intracel-
lular (MDR)Mtb. A complementary human kinome siRNA screen independently confirms the
role of RTK signaling and kinases (BLK, ABL1, and NTRK1) in host control of Mtb. These
approaches validate RTK signaling as a drugable host pathway for HDT against intracellular
bacteria.
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W ith an estimated 1/4 of the world population carrying alatent Mycobacterium tuberculosis (Mtb) infection,10.5 million new cases, and 1.8 million deaths
annually, tuberculosis (TB) is an increasing global health issue1–3.
This is further aggravated by the emergence of multi-, extensively,
and totally drug-resistant (MDR/XDR/TDR) Mtb strains, threa-
tening to render TB untreatable using current antibiotics4–6. In
2015, 480,000 patients suffered from MDR-TB.
Although novel candidate antibiotics have recently been
identified7, current antibiotics already cover the majority of
drugable targets of pathogens, resulting in a continuous decline in
the number of new and approved antibiotics8–13. Intracellular
bacteria such as Salmonellae and Mtb pose additional challenges
by manipulating host-signaling pathways to subvert innate and
adaptive immunity. This, however, also creates potential for novel
treatment strategies like host-directed therapy (HDT), to repro-
gram the host immune system by pharmacological and
chemical–genetic manipulation. Importantly, HDT-driven
manipulation of host-signaling pathways may be effective also
against drug-resistant bacteria, and helps to restore host control
of infection in metabolically perturbed cells14, 15. Several recent
studies, including our own, have demonstrated the feasibility of
HDT approaches to inhibit bacteria both in vitro in human and
murine cells16–20 and in vivo in mice, rabbits, and zebrafish21–31.
Using reciprocal chemical genetics targeting the human kinome,
we previously identified AKT1 as a central regulator of Salmo-
nella enterica serovar Typhimurium (Stm)-, Mtb-, and MDR-Mtb
survival. Treatment of infected cells with the kinase inhibitor H-
89 significantly decreased intracellular bacterial loads. Despite H-
89 being known as a PKA inhibitor, we demonstrated that this
compound inhibited intracellular bacteria by targeting AKT116.
However, H-89 had a substantially lower impact on intracellular
growth of Mtb compared to Stm, suggesting that Mtb modulates
additional host-signaling pathways to survive. This is in agree-
ment with reports thatMtb arrests vesicle maturation at an earlier
stage than Stm16, 32, 33. Other studies identified additional drug-
able human kinases that regulate Mtb survival, including TGFβRI
and CSNK118 and imatinib-sensitive kinases ABL1 and ABL221.
In addition to kinases and kinase inhibitors, other potential tar-
gets and compounds for TB HDT were identified, including two
antipsychotics (haloperidol and prochlorperazine) and an anti-
depressant (nortryptiline)19, phosphodiesterase inhibitors22, 23,
anti-inflammatory agents like ibuprofen25, the FDA-approved
drug zileuton26, the antidiabetic drug metformin34,
phenylbutyrate35, 36, and human metabolic targets37, 38. Never-
theless, the field of TB HDT has not fully progressed toward
clinical application and many interactions between the host and
bacterium remain to be deciphered. Therefore, better compounds
are urgently needed as drug candidates for TB HDT, as well as for
the identification of cellular events occurring at the
host–pathogen interface, which may enable rational drug design
for HDT.
There are several major challenges to be overcome to facilitate
host-directed chemical–genetic studies targeting intracellular
pathogens, particularly studies that aim at discovering key host
pathways manipulated by Mtb. First, it is extremely difficult to
generate sufficient quantities of primary macrophages (Mφs), the
natural target cells for Mtb infection, from human donors for
medium-throughput screens, even by pheresis. Second, the often-
used THP-1 monocytic cell line requires PMA stimulation for
differentiation, which massively affects cell signaling and vesicular
trafficking39, 40, thus confounding cellular signaling studies.
Third, there is a lack of fast (compared to the classical 3-week
Mtb colony-forming unit (CFU) assay), robust, and widely
applicable readouts for rapid screening. Finally, achieving stable
genetic knockdown in human primary macrophages is
challenging, especially in large siRNA screens where knockdown
efficiency of each individual gene cannot broadly be confirmed.
To solve these problems, we have developed a rapid, medium-
throughput, fluorescence-based screening assay to determine
bacterial load by automated flow cytometry in the highly
manipulable human HeLa and MelJuSo cell lines infected with
(myco)bacteria expressing novel (myco)bacterial fluorescent
protein constructs. Our identification of the MelJuSo cell line as a
novel Mtb infection model has several important advantages:
MelJuSo cells are suited to large-scale screening assays as they are
more homogeneous than primary cells, do not require additional
stimuli like PMA for maturation, can be efficiently manipulated
using RNAi, and can be infected by mycobacteria41. We have
shown in the past that human melanocytes can efficiently present
mycobacterial antigens to HLA class II-restricted CD4 T cells42
and have successfully used MelJuSo to dissect molecular pathways
of MHC class II presentation in human cells43, 44. Our novel
fluorescence-based bacterial growth assay is applicable for both
siRNA and chemical compound screens, and is equally suitable
for both Stm and Mtb despite the vast differences in their intra-
cellular “lifestyles” and replication rates (20 min and 18 h,
respectively)6, 32, 45, 46, demonstrating the versatility of this assay.
We used this screening assay in drug-repurposing screens, and
identified compounds with host-directed anti-(myco)bacterial
activity against Mtb and Stm, outperforming published HDT
compounds’ activities. Based on these data, together with con-
firmed target profiles of the screened compounds, we next
developed a predictive in silico model in order to be able to
identify additional HDT compounds. This model was applied to
predict host-directed compounds among all compounds present
in the PubChem repository and to identify their key targets with
predicted activity against intracellular Stm or Mtb. Interestingly,
both our experimental wet lab screens and the novel in silico
predictive model identified inhibitors of (growth factor) receptor
tyrosine kinases (RTKs) and downstream intermediates of RTK
signaling as candidate host-directed drugs to control intracellular
infection. Moreover, an siRNA screen of the human kinome in
Mtb-infected human cells independently validated a key role for
RTK signaling in host control of Mtb. Thus, using two inde-
pendent chemical–genetic experimental approaches as well as a
computational method, we find and validate RTK signaling as a
novel important host pathway that controls intracellular Mtb
(including MDR-Mtb) survival. This pathway is druggable by
compounds and drugs including clinical drugs such as dovitinib,
AT9283, and ENMD-2076. These findings offer new approaches
to combat intracellular infectious diseases in the face of rapidly
rising multidrug resistance.
Results
Flow cytometry-based assay for intracellular bacterial load. To
allow identification of host-directed drugs and host pathways
controlling intracellular bacterial survival, we developed a fast,
robust, and novel assay suited for medium-throughput (96-well)
compound and siRNA screening. Flow cytometry was used to
assay intracellular bacterial load using fluorescent strains of Stm
and Mtb. For initial reference purposes, we tested the kinase
inhibitor H-89, which we had used in previous work16 (Supple-
mentary information, Supplementary Figures 1–4). As men-
tioned, after screening several cell lines, we identified the MelJuSo
cell line as a novel Mtb infection model. To first validate the
MelJuSo model system, we tested already-published host-directed
compounds with known activity against Mtb here in this model;
indeed, as expected, these known compounds also reduced Mtb
loads in MelJuSo cells and in human macrophages upon short
(overnight) treatment (at standard 10 μM concentrations).
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Supplementary Figure 1 describes the assay in more detail. As
shown in Fig. 1, imatinib, D4476, and LY-364947 all decreased
the Mtb bacterial load in our model, which was well in agreement
with previous studies18, 21. In addition, we also confirmed that a
dual inhibitor of TGFbetaR1 and casein kinase 1 (D4476)
inhibited Mtb more potently than the individual inhibitors of
TGFbetaR1 (LY-364947) and casein kinase 1 (IC261) alone,
confirming data from Jayaswal et al.18 (Fig. 1). Finally, during the
work described in this paper also, haloperidol19 was confirmed to
inhibit both Stm andMtb in our model (Table 1) and these results
will be discussed in more detail below. Thus, the results obtained
in our novel MelJuSo-Mtb infection model and flow cytometry-
based readout of intracellular infection faithfully reproduce the
reported inhibitory effects of previously published compounds,
providing important biological plausibility for the system.
Of note, none of the published compounds evaluated above
was more potent in inhibiting intracellular Mtb than our
reference compound H-89. We therefore used our assay to
screen chemical libraries to identify host-directed inhibitors with
more potent activity than H-89.
Identification of host-directed antimicrobial compounds. We
next applied the novel screening assay for a TB drug-repurposing
screen of a library of 1260 pharmacologically active compounds
(LOPAC) in order to identify host-directed compounds with
stronger activity against intracellular Mtb than H-89. The pri-









































Fig. 1 Verification of host-directed Mtb inhibitors from literature in the
novel screening assay. Overnight treatment of MelJuSo cells infected with
Mtb constitutively expressing stable DsRed with compounds that were
previously reported to be active against Mtb at 10 µM or with DMSO at
equal v/v. H-89 is used as a positive control at 10 µM16. The Mtb bacterial
load is displayed as a percentage of the DMSO control± standard deviation
to indicate the extent of bacterial inhibition. Statistically significant
difference compared to DMSO was tested using a one-way ANOVA. (ns
not significant, **p value< 0.01, ***p value< 0.001)
Table 1 Details of validated hit compounds from the Mtb and Stm LOPAC screens










−5.79 −10.51 Src family kinase inhibitor
Q Quinacrine dihydrochloride −5.25 −9.90 MAO inhibitor
SB SB 216763 3-(2,4-Dichlorophenyl)-4-(1-
methyl-1H-indol-3-yl)-1H-pyrrole-
2,5-dione
−6.02 −8.29 GSK-3 kinase inhibitor
G GW5074 3-(3, 5-Dibromo-4-
hydroxybenzylidine-5-iodo-1,3-
dihydro-indol-2-one)
−4.86 −6.98 Raf1 kinase inhibitor
T494 Tyrphostin AG 494 N-Phenyl-3,4-
dihydroxybenzylidene
cyanoacetamide
−3.83 −6.93 EGFR kinase inhibitor
L 3′,4′-Dichlorobenzamil
hydrochloride
L-594,881 −3.87 −5.13 Na+/Ca2+ exchanger inhibitor
H Haloperidol −3.77 −2.96 D2/D1 dopamine receptor
antagonist
Salmonella typhimurium
T Trimethoprim −4.06 −12.18 Antibiotic; dihydrofolate
reductase inhibitor
H Haloperidol −3.90 −12.09 D2/D1 dopamine receptor
antagonist






−3.64 −12.76 Ca2+ channel blocker
O Ofloxacin Ofloxacine; DL-8280; HOE-280 −3.45 −11.60 Antibiotic; DNA synthesis
inhibitor
Z-scores lower than the z-score of H-89 are displayed in bold
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identified 110 compounds that significantly reduced and 16
compounds that increased intracellular bacterial loads. Ninety of
these did not affect host cell viability (Fig. 2a and Supplementary
Table 2) and were therefore pursued further. Seven compounds
decreased Mtb bacterial load more potently than H-89 (Table 1).
A rescreen of these seven compounds confirmed their activity and
five of these compounds again surpassed H-89 (SU 6656, qui-
nacrine, SB 216763, GW5074, and tyrphostin AG 494; Fig. 2b and
Table 1). Figure 2b shows z-score values in the left panel, with the
actual percentage inhibition of Mtb growth shown in the middle
panel, expressed as the % of control value. These latter data
confirmed the strong inhibitory effect of these HDT compounds
on intracellular Mtb. We next confirmed that these compounds
exerted their antimicrobial effects via the host by excluding any
direct microbicidal activity against extracellular Mtb (Fig. 2c). As
a control, the classical Mtb antibiotic rifampicin significantly
inhibited Mtb.
To investigate whether compounds also existed with host-
directed activity against Stm, and whether their activity was
selective forMtb, Stm, or both, we also screened the same LOPAC
library using the very similar HeLa-Stm infection model (Fig. 3a).
Twelve compounds were identified that significantly reduced the
Stm bacterial load and 10 of these did not affect host cell viability
(Supplementary Table 3). A total of 173 compounds increased the
Stm bacterial load without affecting host cell viability. Four of the
hit compounds that decreased the bacterial load (trimethoprim,
haloperidol, mibefradil, and ofloxacin) were superior to H-89 in
inhibiting intracellular Stm (Table 1). Mibefradil again exceeded
the inhibitory effect of H-89 in a rescreen (Fig. 3b), while all four
compounds consistently and strongly decreased the Stm bacterial
load. While Fig. 3a and the left panel of Fig. 3b show z-score
values, the percentage inhibition of intracellular Stm growth is
shown in the middle panel of Fig. 3b, expressed as the % of
control value, demonstrating the strong inhibitory effect of these
HDT compounds on intracellular Stm. We next excluded any
direct microbicidal activity of these HDT compounds against
extracellular Stm (Fig. 3c). By contrast, trimethoprim and
ofloxacin (both known antibiotics), which were part of the
LOPAC library and therefore tested here as well, directly
inhibited extracellular Stm as expected. The fact that these
known antibiotics for Stm were hits in our screen further
confirms the strength and validity of our approach, showing that
we can clearly distinguish antibiotics from host-directed com-
pounds. Taken together, haloperidol (a known HDT inhibitor19)
and mibefradil (newly discovered here) were confirmed and
identified, respectively, as host-directed inhibitors of Stm.
Interestingly, a comparison of the Mtb and Stm HDT
compound screening results revealed a highly limited overlap
between hits in the two infection models (Fig. 3d). This
observation agrees well with reports that Mtb and Stm arrest
vesicle maturation at different stages16, 32, 33. Haloperidol was the
only compound that inhibited both Mtb and Stm.
Identification of HDT compounds using an in silico model. We
next decided to use the above experimental data obtained in our
LOPAC screens, and combine these with bioactivity assay-based
data available for all 1260 LOPAC compounds in PubChem, to
develop a novel bioinformatics predictive model using machine
learning. The model was constructed to predict new chemical
compounds with host-directed activity against intracellular Stm






















































































































































Fig. 2 Identification of host-directed compounds inhibiting Mtb. a Results of a screen of 1260 compounds of the LOPAC library at 10 µM in the MelJuSo-
Mtb infection model using Mtb constitutively expressing stable DsRed, expressed as z-scores (left panel). Individual replicates of the screened compounds
are shown as gray points and the average z-score for each compound is displayed in black. The average z-score and standard deviation of the controls
(DMSO and H-89) are displayed separately and the assay window expressed as a Z′-factor is shown below. Cell viability z-scores of the 110 hit compounds
are shown in the right panel. The dashed line depicts a cutoff at a z-score of −2. b A rescreen of the hit compounds that were superior to H-89 without
affecting cell viability at 10 µM is shown as in a. The bacterial load is expressed as a z-score in the utmost left panel and as a percentage of control value in
the middle panel to indicate the extent of bacterial inhibition. Individual screening datapoints are overlayed on the bar graph. Compound abbreviations: SU
= SU 6656, Q= quinacrine, SB= SB 216763, G=GW5074, T494= tyrphostin AG 494, L= L-594,881, H= haloperidol. c Mtb broth culture treated for
6 days with the five hit compounds of the Mtb screen at 10 µM. Rifampicin (20 μg/ml) was used as a positive control. The average bacterial density±
standard deviation of four replicates from a representative experiment (out of three experiments) is shown, expressed as a percentage of the DMSO
control. Statistically significant difference compared to DMSO was tested using a one-way ANOVA (F(6,25)= 81.66; ***p value< 0.001)
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learning from our own LOPAC screening data (Fig. 4a).
In the Supplementary Information, an extended description of
the machine-learning methods is provided describing the pre-
dictive model. In brief, we first linked all LOPAC compounds to
PubChem, and retrieved bioassay data by using a preprocessing
pipeline (Supplementary Figure 5a), which identified 1058
confirmed human protein targets for these 1260 compounds.
This resulted in a data table comprising all LOPAC compounds
annotated with their corresponding impact on intracellular
bacterial survival and host cell viability from our screens,
expressed as z-scores, and combined with their PubChem
bioassay activity for each confirmed human target. An example
of the table structure is shown in Supplementary Table 4. This
was then used as a training set to learn ensembles of predictive
clustering trees (PCTs; Supplementary Figure 5c) to predict the
impact on intracellular bacterial survival and host cell viability.
We next employed this in silico tool (the learned model) to
identify and select candidate compounds from PubChem with
predicted host-directed antimicrobial activity. Querying Pub-
Chem for compounds that are known to target one or more of
the above 1058 confirmed human protein targets yielded
460,580 compounds, which were then annotated with their
bioassay data and fed into the predictive model as a testing set.
Using the ensembles of PCTs learned from the training data to
predict the intracellular bacterial survival and host cell viability
z-scores of these 460,580 compounds, we identified 47 candidate
compounds predicted to affect intracellular Mtb load
(Supplementary Table 5) and 30 compounds predicted to affect
intracellular Stm load (Supplementary Table 6). From these two
lists of compounds, commercially available compounds
(Table 2) were ordered and screened in the MelJuSo-Mtb and
HeLa-Stm infection models. As the PubChem BioAssay data
contain compound–target relations based only on IC50 and EC50
values as well as binding constants, the predictive model was
able to identify only compound–target interactions rather than
the direction of the target effects. Thus, as we were therefore
unable to predict whether compounds would actually inhibit or
activate their associated targets, predicted negative z-scores
might result in experimentally positive z-scores in in vitro
intracellular bacterial inhibition tests and vice versa. In the Mtb
screen, six out of nine compounds predicted to affect the bac-
terial load indeed decreased or increased the bacterial load
(Fig. 4b, left panel). A rescreen of the hit compounds confirmed
five out of six hits (VEGFR KI I, ENMD-2076, dovitinib,
AT9283, and DAPH 2; Fig. 4b, middle and right panels). The
results are shown as z-scores as well as the percentage inhibition
of Mtb growth expressed as the % of control value, to confirm
the strong inhibitory effect of these HDT compounds on
intracellular Mtb (Fig. 4b, outer right panel).
As compound autofluorescence might result in false-positive z-
scores in our assay, we further validated all the confirmed hit
compounds independently in classical CFU assays, both in cell
lines and in primary human macrophages. The compounds
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Fig. 3 Identification of host-directed compounds inhibiting Stm. a Screen of the LOPAC library in the HeLa-Stm infection model using Stm constitutively
expressing stable DsRed, as in Fig. 2a. b Rescreen of the hit compounds from the HeLa-Stm screen that were superior to H-89 without affecting cell
viability, displayed as in Fig. 2b. The bacterial load is expressed as a z-score in the utmost left panel and as a percentage of control value± standard
deviation in the middle panel to indicate the extent of bacterial inhibition. Compound abbreviations: T= trimethoprim, H= haloperidol, M=mibefradil, O=
ofloxacin. c Overnight treatment of a Stm broth culture with the hit compounds at 10 µM. Gentamicin (50 μg/ml) was used as a positive control. The
average bacterial density± standard deviation of six replicates from a representative experiment out of three experiments is shown. The bacterial load is
expressed as a percentage of the DMSO control value to indicate the extent of bacterial inhibition. Statistically significant difference compared to DMSO
was tested using a one-way ANOVA (F(5,30)= 4871; ***p value< 0.001). d Comparison of the Stm and Mtb primary screening data. Compounds that were
superior to H-89 and subsequently confirmed in a rescreen are indicated in gray triangles. H= haloperidol
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CFUs in both MelJuSo cells and human primary Mφs (Fig. 4c;
results are shown as percentage inhibition of Mtb growth
expressed as % of control value). Importantly, AT9283, ENMD-
2076, and dovitinib also reduced CFUs in human primary
macrophages infected with two different MDR-Mtb strains
(Beijing family China 16319 and Dutch outbreak 2003-1128;
Fig. 4d). These data independently confirm and validate the results
obtained in our novel screening and prediction pipeline, and
importantly extend the newly identified HDT compounds’ effects
to intracellular multidrug-resistant bacteria. Finally, none of the
compounds directly affected extracellular bacterial growth in liquid
cultures, while classical antibiotics (rifampicin) did, confirming
that the mode of action of the new HDT compounds is via
modulation of host and not direct bacterial mechanisms (Fig. 4e).
Using this same screening and validation approach for Stm in
the HeLa-Stm infection model, we confirmed that two out of four
compounds predicted to affect Stm survival indeed decreased the
bacterial load of Stm-infected cells in a primary screen (Fig. 5a,
left panel). Both of these hits (opipramol and nafoxidine) were
subsequently confirmed in a rescreen (Fig. 5a, middle and right
panels; results shown as z-scores and as % inhibition of Stm
growth expressed as the % of control value). Both hit compounds
also reduced the Stm bacterial load independently in classical
CFU assays (Fig. 5b), again without directly affecting bacterial
growth in a liquid overnight Stm culture (Fig. 5c), confirming
their HDT mode of action. These data therefore confirm and
validate our novel screening and prediction pipeline not only for
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Thus, we have successfully developed and used a data-driven
novel in silico predictive model to identify host-directed
compounds with antimicrobial activity against intracellular
bacteria. The model significantly enhanced the identification of
de novo hit compounds (5 out of 9 (55.6%) and 2 out of 4 (50%)
for Mtb and Stm, respectively) compared to random LOPAC
library primary screening (126 out of 1260 (10%) forMtb and 185
out of 1260 (14.6%) for Stm). In addition, the results were
replicated and validated in primary human Mφs infected with
Mtb, strongly agreeing with and further validating the MelJuSo-
Mtb model used in our novel flow cytometry-based screening
assay.
RTK signaling is a novel host pathway controlling Mtb. As
AT9283, ENMD-2076, and dovitinib are RTK inhibitors47–49, we
used a chemical genetics approach to confirm a role for RTK
signaling in host-mediated Mtb control. We first retrieved human
protein targets of AT9283, ENMD-2076, and dovitinib from the
Compound Bioactivity section in ChEMBL (http://www.www.ebi.
ac.uk/chembl/) and further downselected targets for which the
compounds were annotated as “Active.” Because no targets
annotated as “Active” could be retrieved for AT9283 and ENMD-
2076, we first constructed a STRING protein network and per-
formed gene ontology (GO) analysis using the targets of dovitinib
(n = 86 proteins; Fig. 6a). Due to the hierarchical organization of
GO terms, general cellular and molecular functions tend to be
highly enriched in GO term enrichment analyses. Therefore, we
focused on identifying the highest-ranked GO terms that
described distinct pathways rather than the overall highest-
ranked GO terms. As expected from the reported target specifi-
cities of dovitinib49, “transmembrane receptor protein tyrosine
kinase signaling pathway” (GO:0007169, false-discovery rate
(FDR) 3.82E−33) was the highest-ranking enriched pathway and
40 protein targets participated in this pathway (Fig. 6a and
Supplementary Figure 6a). We next verified that both AT9283
and ENMD-2076 target RTKs by retrieving human protein tar-
gets from the Target Summary section in ChEMBL and per-
formed an identical STRING analysis (Supplementary Figure 6b,
c). Even though this analysis resulted in small networks due to the
limited number of studied targets and the lists of targets from the
Target Summary section also include nonconfirmed targets, the
GO term “transmembrane receptor protein tyrosine kinase sig-
naling pathway” (GO:0007169) was again highly enriched in the
target networks of AT9283 (FDR 1.11E−12) and ENMD-2076
(FDR 6.47E−5).
To independently confirm RTK signaling as a functional
pathway that controls intracellular survival of Mtb, we next
performed an unbiased siRNA screen of the human kinome in
the MelJuSo-Mtb infection model (Fig. 6b), agnostic to the above
data. The siRNA screen identified 20 targets that decreased and
21 that increased the Mtb bacterial load while not affecting host
cell viability (Table 3). These 41 hit kinases were then used in a
STRING protein network and GO analysis. Independently
confirming the STRING analysis of the targets of dovitinib,
AT9283, and ENMD-2076, also, in this analysis, again “trans-
membrane receptor protein tyrosine kinase signaling pathway”
(GO:0007169, FDR 1.32E−13) was the highest-ranking enriched
pathway, and 18 hit kinases from the siRNA screen participated
in this pathway (Fig. 6c and Supplementary Figure 6d). Three of
the kinases (ABL1, BLK, and NTRK1) were both hits in the
siRNA screen and confirmed targets of dovitinib (Fig. 6d). Of
these three kinases, only ABL1 was present in the potential target
networks of AT9283 and ENMD-2076 (Supplementary Figure 6b,
c). However, a lower dissociation constant (Ki) is reported in
ChEMBL for the interaction between dovitinib and BLK (Ki:
12.59 nM) than between dovitinib and ABL1 (Ki: 100 nM),
suggesting that BLK is targeted more strongly by dovitinib. To
identify the top-enriched RTK signaling pathway targeted by
dovitinib and siRNA, we used the kinases shown in Fig. 6d in a
STRING analysis. This identified the neurotrophin signaling
pathway as the top-enriched KEGG pathway (Fig. 6e)50. Silencing
of neurotrophic receptor tyrosine kinase 1 (NTRK1) resulted in
an increased Mtb bacterial load (Table 3), establishing a
functional link between neurotrophin signaling and Mtb survival.
Thus, using independent chemical, genetic, functional, and
computational approaches, we find and validate that (1) RTK
signaling is a novel host pathway that controls intracellular
(MDR)-Mtb survival and that (2) repurposable drugs such as
dovitinib, AT9283, and ENMD-2076 that target RTK signaling
are new candidates for HDT in treating TB, including multidrug-
resistant Mtb.
Discussion
Employing chemical genetic screens complemented with newly
developed computational approaches, we have identified host-
directed therapy (HDT) compounds and drugs (dovitinib,
Fig. 4 Screen of in silico-predicted chemical compounds active against intracellular Mtb. a Schematic overview of the in silico predictive model. BLoad=
bacterial load z-score, CViab= cell viability z-score. b Chemical compound primary screen (left panel) and rescreen (middle panel) at 10 µM in the
MelJuSo-Mtb infection model using Mtb constitutively expressing stable DsRed, expressed as mean z-scores± standard deviation. Horizontal dashed lines
indicate a hit cutoff at a z-score of 2 or −2. The average z-score and standard deviation of the controls (DMSO and H-89) are displayed separately. To
indicate the extent of bacterial inhibition, rescreen results are expressed both as z-score and as a percentage of control value± standard deviation in the
right panel. c CFU assay of the MelJuSo (left panel) and human primary Mφ1 (middle panel) and Mφ2 (right panel) Mtb infection models treated with the
validated hit compounds from b at 10 µM. Mφ1 and Mφ2 models have been described by Verreck et al.78. Representative data out of three independent
experiments (MelJuSo) and data from a representative donor (Mφs) out of two (Mφ1) or five (Mφ2) different healthy blood bank donors are shown. To
indicate the extent of bacterial inhibition, the results are expressed as a percentage of control value± standard deviation. Number of replicates in the
MelJuSo model: AT9283 and ENMD-2076: n= 6; dovitinib, VEGFR KI I, and DAPH 2: n= 5; DMSO and H-89: n= 9. Number of replicates in the Mφ
models: AT9283, ENMD-2076, dovitinib, VEGFR KI I, and DAPH 2: n= 3; DMSO and H-89: n= 5. Statistically significant difference compared to DMSO
was tested using a one-way ANOVA (MelJuSo: F(6,39)= 16.35; Mφ1: F(6,18)= 10.88; Mφ2: F(6,18)= 5.23; *p value< 0.05, **p value< 0.01, ***p value<
0.001). d CFU assay of the human primary Mφ1 and Mφ2 models infected with two different MDR-Mtb strains (Beijing family China 16319 and Dutch
outbreak 2003-1128) and treated with the validated hit compounds from c at 10 µM. Data (n= 3 technical replicates) from a representative donor out of
four different healthy blood bank donors, displayed as a percentage of the DMSO control± standard deviation are shown. Statistically significant
differences compared to DMSO were tested using a one-way ANOVA (Mφ1 Beijing: F(4,10)= 11.43; Mφ2 Beijing: F(4,10)= 3.72; Mφ1 Dutch outbreak: F(4,10)
= 29.09; Mφ2 Dutch outbreak: F(4,10)= 8.81; *p value< 0.05, **p value< 0.01, ***p value< 0.001). e Six-day treatment of Mtb broth cultures with the hit
compounds at 10 µM. The Mtb antibiotic rifampicin (20 μg/ml) was used as a positive control. The average bacterial density± standard deviation of three
replicates is shown, expressed as a percentage of the DMSO control. Representative results out of three individual experiments are displayed. Statistically
significant difference compared to DMSO was tested using a one-way ANOVA (F(6,25)= 101.4; **p value< 0.01, ***p value< 0.001)
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AT9283, and ENMD-2076) that target human RTK signaling to
control intracellular Mtb survival, including MDR-Mtb. Perhaps,
more importantly, our findings pave the way toward identifying
additional compounds targeting human RTK signaling to
improve control of intracellular Mtb infection since all com-
pounds were confirmed to be effective in primary human mac-
rophage infection models.
Current efforts to develop HDT are a topic of interest for
infectious diseases and cancer (reviewed recently38). In order to
be able to screen larger HDT compound libraries for novel leads
with activity against intracellular Mtb and Stm, we have devel-
oped a new robust and rapid fluorescence-based intracellular
screening assay. This assay allowed us to identify host-directed
Mtb-inhibiting compounds (SU 6656, quinacrine, SB 216763,
GW5074, and tyrphostin AG 494) and host-directed Stm-inhi-
biting compounds (mibefradil), which performed significantly
better than our best reference compound H-89, in a LOPAC
library drug-repurposing screening effort. We were also able to
confirm the activity of previously published HDT compounds in
our screening approach (imatinib, D4476, LY-364947, and halo-
peridol), lending strong plausibility and validity to our strategy.
We next developed a novel in silico model which was data
driven and based on known and confirmed targets from public
databases, by which we could successfully predict and verify
additional compounds with host-directed activity against Mtb
(dovitinib, AT9283, and ENMD-2076) and Stm (nafoxidine and
opipramol). Using STRING network analysis, we uncovered RTK
signaling as a novel host pathway controlling Mtb intracellular
survival, which is targeted by compounds identified in this study.
Finally, we performed an independent unbiased siRNA screen of
the human kinome, which confirmed a role for RTK signaling in
control of intracellular Mtb survival. Collectively, our results
uncover new host-signaling pathways as well as the correspond-
ing active chemical compounds targeting these to control intra-
cellular bacterial infections, including MDR-TB and Stm.
Our LOPAC screen provides an important and general proof of
principle for drug repurposing, since we successfully identified
several candidate compounds that displayed host-directed
antimicrobial activity while their known targets have not pre-
viously been associated with infectious diseases. Strikingly, four of
the five hit compounds that consistently outperformed H-89 in
controlling Mtb infection are known to affect (growth factor)
RTK signaling. Tyrphostin AG 494, SU 6656, SB 216763, and
GW5074 are inhibitors of EGFR, SRC family kinases (SFKs),
GSK-3, and RAF1, respectively, which are all kinases participating
in RTK pathways51–55. In addition to compounds affecting RTK
signaling, we identified three other host-directed Mtb-inhibiting
compounds with vastly different target specificities. First, quina-
crine was originally developed as an antimalarial drug but has
displayed activity in a myriad of diseases via a wide range of
targets56. Interestingly, reported targets of quinacrine include
AKT1 and NF-κB as well as phospholipase A257. The latter is a
central enzyme in the eicosanoid pathway, which was recently
shown to be involved in Mtb control by balancing the type I
interferon response26. Second, haloperidol is an antipsychotic
drug targeting dopamine receptors58. Importantly, haloperidol
was recently shown to affect survival of intracellular mycobacteria
in a host-directed fashion19, providing important additional and
independent validation of our screening strategy and models.
Finally, 3′,4′-dichlorobenzamil is an amiloride-analog Na+/Ca2+
exchanger inhibitor59. This compound may act by inhibiting Ca2+
transport in the cell, as activation of calcineurin by increased Ca2+
levels has previously been proposed as a mechanism for inhibi-
tion of phagosome maturation in Mtb-infected cells60.
A similar LOPAC library screen in the HeLa-Stm infection
model resulted in four compounds that more strongly reduced
the bacterial load than our reference compound H-89, and
mibefradil was further confirmed to surpass H-89’s activity in a
rescreen. However, H-89 is already a highly potent host-directed
inhibitor of Stm and all four compounds consistently and sig-
nificantly reduced the Stm bacterial load. Two of the four hit
compounds from the primary screen were known antibiotics
(trimethoprim and ofloxacin) but these were tested nevertheless
in our screen because they were part of the LOPAC. Of the
remaining two HDT compounds, haloperidol, which was already
found in a previous HDT screen study in TB, was confirmed as a


















10113978 Pazopanib·HCl −2.30 −0.91 0.53 −1.50 ND Receptor tyrosine kinase
(RTK) inhibitor
11496629 AT9283 −2.27 −0.95 0.54 4.01 6.09 JAK/Aurora kinase inhibitor
16041424 ENMD-2076 −2.15 −0.89 0.54 −3.62 −2.83 RTK/Aurora A inhibitor
11485656 Linifanib (ABT-869) −2.11 −0.87 0.54 −3.13 0.66 VEGFR/PDGFR inhibitor
10907042 PDGFR Tyrosine Kinase
Inhibitor III
−2.24 −0.88 0.53 1.19 ND PDGFR inhibitor
9977819 Dovitinib (TKI-258,
CHIR-258)
−2.14 −0.93 0.53 −3.70 −2.02 RTK inhibitor
6419834 VEGFR2 Kinase Inhibitor I −2.14 −0.93 0.53 −3.91 −7.63 VEGFR2 inhibitor
6711154 DAPH 2 −2.08 −0.93 0.68 136.21 80.77 PKC inhibitor
24889392 Quizartinib −2.00 −0.87 0.65 −0.24 ND FLT3 inhibitor
Salmonella typhimurium
4416 Nafoxidine hydrochloride −1.52 0.44 0.73 −3.06 −2.33 Estrogen receptor modulator
7333 1,3-Di-o-tolylguanidine −1.56 0.04 0.66 −0.42 ND Sigma 1 receptor agonist
47641 Naftifine hydrochloride −1.52 0.44 0.73 −0.61 ND Fungal squalene epoxidase
inhibitor
9417 Opipramol −1.51 0.15 0.69 −4.01 −4.21 Sigma receptor agonist
ND not determined
Z-scores exceeding the cutoff (2< z-score< –2) are displayed in bold
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HDT compound with activity against Mtb, but we extend these
results here to Stm as well. These data again show the validity of
our screening and prediction approach since we are able to
consistently and faithfully confirm already-available knowledge.
The data on haloperidol also suggest that this compound may be
applicable for HDT in a broader spectrum of intracellular bac-
terial infections. The second hit compound, mibefradil, is a Ca2+
channel blocker61. The majority of screening hits in the HeLa-
Stm infection model exacerbated bacterial loads and even though
these compounds can therefore not be used for drug repurposing,
all of the identified compounds may be important starting points
for gaining deeper mechanistic insight into Stm–host interactions.
The limited overlap between the hit compounds from Mtb and
Stm screens likely reflects the vastly different intracellular “life-
styles” of these pathogens. Notwithstanding this, several com-
pounds display consistent intracellular antimicrobial activity in
both Mtb and Stm infection models, such as haloperidol. These
compounds are therefore promising candidate drugs with wider
application against (antibiotic resistant) intracellular bacterial
infections.
Selecting hits for follow-up analysis in large (chemical) screens
poses substantial challenges. Here, we employed two com-
plementary strategies for screening follow-up. First, as we aimed
to identify compounds with superior host-directed antimicrobial
activity, we focused on compounds performing better than the
reference compound H-89, resulting in a strictly data-driven hit
cutoff. Using this strategy, we identified SU 6656, quinacrine, SB
216763, GW5074, and tyrphostin AG 494 as the most promising
candidate compounds for TB and mibefradil for salmonellosis, as
well as confirmed haloperidol as an attractive drug for HDT
against both Mtb and Stm. Second, as screening outcome may be
strongly influenced by compound properties such as solubility,
hydrophobicity, concentration, IC50, and target selectivity, using a
strict cutoff may mask valuable data hidden in the large data set
and will be lost to follow-up. We therefore used a complementary
follow-up approach by developing an innovative in silico com-
pound predictive model to uncover relevant chemical compound
classes and target profiles in screening data. Focusing on con-
firmed target profiles by automated extraction of bioassay data
from PubChem, we were able to both discern compound targets
and predict novel active compounds. As the target profiles were
ranked without using a hit cutoff, this approach enabled unbiased
validation and follow-up of the primary chemical compound
screen. The use of simple numerical values as predictive para-
meters renders this prediction model highly adaptable and easily
applicable to other chemical screens. The model significantly
enhanced the identification of de novo hit compounds (55.6%
and 50% for Mtb and Stm, respectively) compared to random
LOPAC library primary screening (10% for Mtb and 14.6% for
Stm). Remarkably, the predicted Mtb hit compounds AT9283,
ENMD-2076, and dovitinib were all (growth factor) RTK inhi-
bitors47–49.
As inhibitors of RTK signaling molecules were already
observed to be overrepresented in the hits from our drug-
repurposing screen, our predictive model successfully provided an
unbiased validation of this observation and prompted us to fur-
ther focus our screening endeavor on RTK inhibitors. RTK
inhibitors are widely studied in cancer research for their anti-
neoplastic properties62. Phase II clinical trials have been per-
formed with both AT9283 and ENMD-2076 and dovitinib has
already passed phase III clinical trials63–68 (http://www.
clinicaltrials.gov), enabling swift future drug repurposing as
host-directed antimicrobials. Our unbiased siRNA screen of the
human kinome independently identified and validated RTK sig-
naling as a host pathway regulatingMtb survival, identifying BLK,
ABL1, and NTRK1 as host kinases, and controlling intracellular
Mtb and possible drugable targets. BLK is an SFK involved in B
cell receptor signaling and the insulin response to glucose uptake
in pancreatic islet cells69, 70. The non-receptor tyrosine kinase
ABL1 was previously linked to mycobacterial infection and its
commonly used inhibitor imatinib was shown to exert host-
directed Mtb-inhibiting activity in vivo15, 21, providing indepen-
dent validation of our siRNA screening. Finally, NTRK1 is an






































































































































































































Fig. 5 Screen of in silico-predicted chemical compounds active against intracellular Stm. a Chemical compound primary screen (left panel) and rescreen
(middle panel) at 10 µM in the HeLa-Stm infection model using Stm constitutively expressing stable DsRed, expressed as mean z-scores± standard
deviation. Horizontal dashed lines indicate a hit cutoff at a z-score of 2 or −2. The average z-scores and standard deviations of the controls (DMSO and H-
89) are displayed separately. To indicate the extent of bacterial inhibition, rescreen results are expressed as a percentage of control value± standard
deviation in the right panel. b CFU assay of the HeLa-Stm infection model treated with the validated hit compounds from a at 10 µM. Representative data
out of three independent experiments, displayed as a percentage of the DMSO control are shown. The average± standard deviation of three replicates is
shown. Statistically significant differences compared to DMSO were tested using a one-way ANOVA (F(3,8)= 56.31; ***p value< 0.001). c Overnight
treatment of Stm broth cultures with the hit compounds at 10 µM. The Stm antibiotic gentamicin (50 μg/ml) was used as a positive control. The average
bacterial density± standard deviation of three replicates is shown, expressed as a percentage of the DMSO control. Representative results out of three
individual experiments are displayed. Statistically significant differences compared to DMSO were tested using a one-way ANOVA (F(3,38)= 579.5; ***p
value< 0.001)
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synaptic function and plasticity71. Various cells of the hemato-
poietic lineage have been shown to produce the NTRK ligand
nerve growth factor during inflammation and autoimmunity72
and expression of NTRKs in monocytes has been previously
reported73. Next to the confirmation of these compound targets
by genetic silencing as described here, there were other siRNA
hits involved in RTK signaling which might represent as-yet-
unknown molecular targets for these or other hit compounds.
Conversely, confirmed compound targets that were not identified
in our siRNA screen may still contribute to Mtb control due to
redundancy and possible incomplete genetic knockdown inherent
to siRNA screens.
A role for growth factors in mycobacterial infection has been























#pathway ID Pathway description
Gene
count FDR
GO.0006468 Protein phosphorylation 78 1.82E–104
GO.0006796 Phosphate-containing compound metabolic process 77 5.02E–75
GO.0046777 Protein autophosphorylation 48 5.02E–75
GO.0006464 Cellular protein modification process 77 2.12E–62
GO.0018108 Peptidyl-tyrosine phosphorylation 37 3.82E–55
GO.0018193 Peptidyl-amino acid modification 51 3.73E–48
GO.0035556 Intracellular signal transduction 57 3.48E–40
GO.0007169 Transmembrane receptor protein tyrosine kinase signaling pathway 40 3.82E–35
GO.0001934 Positive regulation of protein phosphorylation 40 7.72E–33
GO.0007167 Enzyme linked receptor protein signaling pathway 41 7.77E–32
#pathway ID Pathway description
Gene
count FDR
GO.0016310 Phosphorylation 36 2.07E–38
GO.0006468 Protein phosphorylation 29 1.86E–29
GO.0044267 Cellular protein metabolic process 30 1.32E–13
GO.0007169 Transmembrane receptor protein tyrosine kinase signaling pathway 18 1.32E–13
GO.0018108 Peptidyl-tyrosine phosphorylation 10 3.76E–10
GO.0035556 Intracellular signal transduction 21 6.49E–10
GO.0046777 Protein autophosphorylation 10 2.44E–09
GO.0007166 Cell surface receptor signaling pathway 20 5.30E–08
GO.0044237 Cellular metabolic process 35 7.52E–08























































































































































































































































#pathway ID Pathway description
Gene
count FDR
4722 Neurotrophin signaling pathway 15 1.95e–19
4014 Ras signaling pathway 15 2.01e–15
4151 PI3K-Akt signaling pathway 16 3.13e–14
4664 Fc epsilon RI signaling pathway 10 1.12e–13
4015 Rap1 signaling pathway 13 3.15e–13
4510 Focal adhesion 13 3.15e–13
4660 T cell receptor signaling pathway 10 3.99e–12
4380 Osteoclast differentiation 10 3.56e–11
4062 Chemokine signaling pathway 1 4.34e–11
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mycobacterial infection in a zebrafish Mycobacterium marinum
(Mmar) infection study28 as well as in a rabbit Mtb infection
model27. However, in both studies, the reported effect of VEGF
was primarily systemic rather than (sub)cellular, inducing
enhanced angiogenesis in granulomas. Our data strongly suggest
that an intracellular response to growth factor receptor signaling
via RTKs may be another important determinant for myco-
bacterial infection outcome. Interestingly, Oehlers et al. used
pazopanib, one of the compounds identified by our predictive
model to show an inhibitory effect of VEGF receptor (VEGFR)
inhibition on vascularization around nascent granulomas in their
model. Though not meeting our strict hit selection criteria,
pazopanib statistically significantly (z-score –1.50) decreased Mtb
loads in our screen (and thus in the absence of a vascular system),
suggesting that cellular Mtb inhibition by pazopanib might pre-
cede or complement the vascularization effects observed in vivo
by Oehlers et al. Additionally, epidermal growth factor receptor
(EGFR) signaling has previously been linked to mycobacterial
infection through a chemical screen identifying EGFR inhibitor
gefitinib as a compound that restricts Mtb growth31. Our study
significantly expands this knowledge by introducing additional
RTK-targeting compounds that can be used for drug repurposing,
including compounds targeting VEGFR (dovitinib) and EGFR
(tyrphostin AG 494) signaling.
Our in silico predictive model successfully identified two
compounds (nafoxidine, an estrogen receptor modulator and
opipramol, a sigma receptor agonist) with host-directed Stm-
inhibiting activity. Interestingly, haloperidol (a hit in both the
Mtb and Stm LOPAC screens) was previously reported to interact
with sigma receptors with high affinity74, suggesting mechanistic
involvement of sigma receptors in host control of intracellular
bacteria.
Finally, the development and validation of a novel
fluorescence-based screening assay that is able to rapidly quantify
intracellular bacterial infection in human cells, as described here,
we think that it is important since it helps shortening the readout
from a classical 3-week CFU assay for Mtb to 24–72 h using flow
cytometry. The assay is highly reproducible, medium throughput,
provides an excellent assay window, and is suitable for screening
both chemical compound and siRNA libraries. Taking advantage
of the previously reported phagocytic capability of melanocytes41,
we also report the human melanoma cell line MelJuSo as a novel
model for Mtb infection studies, particularly for studies encom-
passing chemical and RNAi screens. Importantly, our assay
faithfully reproduces the inhibitory effect of several previously
published host-directed compounds (that were identified using
different strategies, approaches, and models) on Mtb intracellular
survival, as well as HDT results obtained in human primary
macrophages, further validating our novel infection model.
Fig. 6 Identification of host kinases controlling intracellular Mtb survival. a STRING network of confirmed targets of dovitinib retrieved from the ChEMBL
repository Compound Bioactivity section (left panel). Individual proteins are displayed as nodes. Lines represent protein–protein interactions and the
thickness of the lines indicates confidence. Proteins participating in the “transmembrane receptor tyrosine kinase signaling pathway” are displayed in red.
The top 10 enriched GO terms in the “Biological Function” category are displayed along with the number of genes/proteins annotated with the indicated
GO terms and the false-discovery rate (FDR) of the enrichment (right panel). b Results of a siRNA screen of the human kinome in the MelJuSo-Mtb
infection model using Mtb constitutively expressing destabilized DsRed, expressed as z-scores. The average z-score± standard deviation for each siRNA
pool is displayed. A hit cutoff at z= 2 or z= –2 is displayed as a dashed line. The average z-score and standard deviation of the controls (siCTRL and siAKT)
are displayed separately. SiCTRL: nontargeting siRNA pool. c STRING network of the siRNA screen hits (left panel) is displayed along the top 10 enriched
GO terms in the “Biological Function” category (right panel), as in a. d Participation of individual targets of dovitinib (top row) or hits from the siRNA
screen (bottom row) in the “transmembrane receptor tyrosine kinase signaling pathway” are indicated by filled squares. Proteins that are both targeted by
dovitinib and were a hit in the siRNA screen are shown in magenta. Dissociation constants (Ki) retrieved from ChEMBL are shown below for the interaction
between dovitinib and ABL1, BLK, and NTRK1. e STRING analysis to identify enriched KEGG pathways using the kinases from d. The top 10 enriched KEGG
pathways along with the number of genes/proteins annotated with the indicated GO terms and the FDR of the enrichment are displayed (left panel).
Involvement of individual proteins is overlaid on the “neurotrophin signaling pathway” KEGG pathway retrieved from the Kyoto Encyclopedia of Genes and
Genomes (http://www.genome.jp/kegg/). Proteins in gray are targeted by dovitinib only, blue proteins were siRNA screening hits, and proteins in red are
both targeted by dovitinib and silencing of these genes affected the Mtb bacterial load
Table 3 siKinome screen hits in the MelJuSo-Mtb infection
model
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In conclusion, the results from our chemical, genetic, and novel
bioinformatics approach provide an important proof of concept
of HDT for intracellular infections, such as (MDR) TB and sal-
monellosis. Moreover, our results identify human RTK signaling
as a signaling pathway targetable by novel repurposable drugs,
providing a new and promising therapeutic starting point for
drug development against Mtb, including MDR-Mtb.
Methods
Reagents. H-89 dihydrochloride, D4476, IC261, LY-364947, DAPH 2, nafoxidine
hydrochloride, 1,3-di-o-tolylguanidine, naftifine hydrochloride, opipramol, rifam-
picin, kanamycin, and the library of pharmacologically active compounds
(LOPAC) were purchased from Sigma-Aldrich, Zwijndrecht, the Netherlands.
Hygromycin B was acquired from Life Technologies-Invitrogen, Bleiswijk, the
Netherlands. Imatinib mesylate was from Enzo Life Sciences, Raamsdonksveer, the
Netherlands. VEGFR2 kinase inhibitor I and ampicillin were purchased from
Calbiochem Merck-Millipore, Darmstadt, Germany. Pazopanib HCl, AT9283, and
linifanib (ABT-869) were acquired from Selleck Chemicals, Munich, Germany.
Quizartinib was purchased from MedChemExpress, Stockholm, Sweden. Santa
Cruz BioTechnology, Heidelberg, Germany was the supplier of PDGFR tyrosine
kinase inhibitor III. Dovitinib (TKI-258, CHIR-258) was from APExBIO, Houston,
TX, USA. The siKinome library was acquired from Thermo Fisher Dharmacon,
Waltham, MA, USA.
Cell culture. HeLa cells and the MelJuSo human melanoma cell line were main-
tained at 37 °C and 5% CO2 in Gibco Iscove’s Modified Dulbecco’s Medium (IMDM;
Life Technologies-Invitrogen) with 10% fetal bovine serum (FBS, Greiner Bio-One,
Alphen a/d Rijn, the Netherlands), 100 units/ml penicillin and 100 µg/ml strepto-
mycin (Life Technologies-Invitrogen). Proinflammatory Mφ1s and anti-
inflammatory Mφ2s were generated from monocytes isolated from whole blood of
healthy donors by FICOLL separation and CD14 MACS sorting (Miltenyi Biotec,
Teterow, Germany) followed by 6 days of differentiation with 5 ng/ml granulocyte
macrophage–colony-stimulating factor (GM–CSF; BioSource Life Technologies-
Invitrogen) or 50 ng/ml macrophage–colony-stimulating factor (M–CSF; R&D
Systems, Abingdon, UK), respectively, as previously reported75. Mφs were cultured
in Gibco Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies-
Invitrogen) with 10% FBS and 2mM L-alanyl-L-glutamine (PAA, Linz, Austria).
Bacterial culture. Bacterial strains used are displayed in Supplementary Table 1.
Mycobacteria were cultured in Difco Middlebrook 7H9 broth (Becton Dickinson,
Breda, the Netherlands) supplemented with 10% ADC (Becton Dickinson), 0.5%
Tween-80 (Sigma-Aldrich), and appropriate antibiotics. Stm was cultured on Difco
Luria-Bertani (LB) agar (Becton Dickinson) or in Difco LB broth (Becton Dick-
inson) supplemented with appropriate antibiotics.
Stm and Mtb infections. One day before infection, mycobacterial cultures were
diluted to a density corresponding with early log-phase growth (optical density at
600 nm (OD600) of 0.4). Stm was grown either in LB broth or on LB agar with
appropriate antibiotics. After overnight incubation, Stm liquid cultures were
diluted 1:33 and cultured for an additional 3–4 h, while plate-grown Stm was
suspended in PBS by rinsing the agar plates. Bacterial density was determined by
measuring the OD600 and the bacterial suspension was diluted in cell culture
medium without antibiotics to reach a multiplicity of infection (MOI) of 10 (unless
indicated otherwise). Accuracy of bacterial density measurements was verified by a
standard colony-forming unit (CFU) assay. Cell cultures (HeLa for Stm infections
and MelJuSo for Mtb infections), seeded in 96-well flat-bottom plates as described
below, were inoculated with 100 μl of the bacterial suspension, centrifuged for 3
min at 800 rpm, and incubated at 37 °C/5% CO2 for 20 min if infected with Stm or
60 min if infected with Mtb. The plates were then washed with culture medium
containing 30 μg/ml gentamicin sulfate (Lonza BioWhittaker, Basel, Switzerland)
and incubated at 37 °C and 5% CO2 in a medium containing 5 μg/ml gentamicin
and the indicated chemical compounds until readout by flow cytometry or CFU, as
indicated.
Chemical compound treatment. A total of 10,000 HeLa or MelJuSo cells were
seeded per well in 96-well flat-bottom plates or 300,000 primary macrophages were
seeded per well in 24-well plates in appropriate culture medium without antibiotics
1 day prior to infection with Mtb or broth-grown Stm. Infected cells were treated
overnight with chemical compounds at 10 μM (unless indicated otherwise) or
DMSO at equal v/v in a medium containing 5 μg/ml gentamicin.
siRNA transfections. A total of 3,000 HeLa or MelJuSo cells were reverse-
transfected with ON-TARGETplus siRNA pools (Thermo Fisher Dharmacon,
Waltham, MA, USA) at a 50 nM concentration using 0.2 μl of Dharmafect1
(Thermo Fisher Dharmacon) per well in a flat-bottom 96-well plate in appropriate
culture medium without antibiotics. Knockdown efficiency was verified by
immunoblotting at the indicated time points. Cells transfected with siRNA were
infected with Mtb at MOI 1000 24 h post transfection and incubated for an
additional 48 h and infections with agar-grown Stm were carried out at MOI 500
72 h post transfection and incubated overnight, unless indicated otherwise.
Colony-forming unit assay. CFU assays were performed using the track dilution
method described previously76. In short, bacterial suspensions were serially diluted
and 10-μl drops were plated on square agar plates, which were subsequently placed
at an angle to allow the drops to spread over a larger surface area.
Bacterial growth assay. A volume of 100 μl of Stm or Mtb culture (OD600 of 0.1)
was plated in a flat-bottom 96-well plate containing 100 μl of indicated chemical
compounds at 20 μM in LB (Stm) or 7H9 (Mtb) broth. The plate was incubated at
37 °C overnight for Stm or during a period of 15 days for Mtb and absorbance was
measured at a 550-nm wavelength on a Mithras LB 940 plate reader (Berthold
Technologies, Bad Wildbad, Germany).
Fluorescence microscopy. A total of 100,000 HeLa or MelJuSo cells were grown
on glass coverslips (Menzel-Gläser, Braunschweig, Germany) in 24-well plates and
infected as described above. Samples were fixed for 30 min at RT with 4% paraf-
ormaldehyde, embedded in VectaShield with DAPI (Brunschwig Chemie,
Amsterdam, the Netherlands), and examined on an Axioskop 2 fluorescence
microscope (Carl Zeiss, Sliedrecht, the Netherlands).
STRING analysis. Protein interaction networks were generated using STRING
version 10 (http://string-db.org/)77 using experiments and databases as data
sources and a minimal confidence score of 0.4.
Statistics. Student’s t test, one-way ANOVA, and linear regression were per-
formed using GraphPad Prism version 6.0 for Mac OS X (GraphPad Software, San
Diego, CA, USA; www.graphpad.com).
Data availability. The data that support the findings of this study are available
from the corresponding authors on request.
Code availability. The code of the machine-learning software CLUS that was used
to build the in silico models for predicting compound activity is available for
download from the SourceForge repository (at https://sourceforge.net/projects/clus/).
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